Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
222 participants
OBSERVATIONAL
2019-01-15
2023-06-19
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effectiveness and Adherence of Golimumab in Rheumatoid Arthritis
NCT04188249
A Study of the Safety and Efficacy of Golimumab (CNTO 148) in Subjects With Active Rheumatoid Arthritis Previously Treated With Biologic Anti-TNFa Agent(s)
NCT00299546
A Safety and Efficacy Study of Golimumab (CNTO148) in Patients With Active Rheumatoid Arthritis (RA)
NCT00771251
An Effectiveness and Safety Study of Intravenous Golimumab in Patients With Active Rheumatoid Arthritis Despite Treatment With Methotrexate Therapy
NCT00973479
Observational Study of Golimumab Intravenous Infusion
NCT02390700
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Participants with Diagnosis of Rheumatoid Arthritis
Participants will not receive any intervention as a part of this study. All Rheumatoid Arthritis (RA) participants treated with golimumab in a clinical practice setting will be observed.
Golimumab
Participants will receive golimumab as a part of clinical practice.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Golimumab
Participants will receive golimumab as a part of clinical practice.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* About to initiate therapy with golimumab
* Must sign a participation agreement/informed consent form (ICF) allowing data collection and source data verification in accordance with local requirements
Exclusion Criteria
* Received an investigational drug (including investigational vaccines) or used an invasive investigational medical device within 90 days before the start of the study or the first data collection time point
* Currently enrolled in an investigational study
* Currently enrolled in an observational study sponsored or managed by a Janssen company
18 Years
85 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Janssen Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Janssen Inc. Clinical Trial
Role: STUDY_DIRECTOR
Janssen Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Peak Medical Specialty Centre
Calgary, Alberta, Canada
Jacqueline C Stewart Medical Inc.
Penticton, British Columbia, Canada
Dr. Milton F Baker Inc.
Victoria, British Columbia, Canada
Fredericton Medical Clinic
Fredericton, New Brunswick, Canada
Nexus Clinical Research
St. John's, Newfoundland and Labrador, Canada
St Clare's Hospital
St. John's, Newfoundland and Labrador, Canada
Private Practice - Dr. Diane Wilson
Lunenburg, Nova Scotia, Canada
The Waterside Clinic
Barrie, Ontario, Canada
Dr. Sankalp V. Bhavsar Medicine Professional Corporation
Burlington, Ontario, Canada
Private Practice - Dr. Pauline Boulos
Dundas, Ontario, Canada
Dr. Sangeetha Thiviyarajah Medicine Professional Corporation
Etobicoke, Ontario, Canada
Samuel Silverberg Medicine Professional Corporation
Etobicoke, Ontario, Canada
Adachi Medicine Professional Corporation
Hamilton, Ontario, Canada
Manisha Mulgund Medicine Professional Corporation
Hamilton, Ontario, Canada
K-W Musculoskeletal Research Inc
Kitchener, Ontario, Canada
Markham Rheumatology Hub
Markham, Ontario, Canada
Credit Valley Rheumatology
Mississauga, Ontario, Canada
Dr. Rajwinder S Dhillon Medicine Professional Corporation
Niagara Falls, Ontario, Canada
Makhzoum Medicine Professional Coporation
Oakville, Ontario, Canada
Dr. S. Gill Medicine Professional Corporation
Oakville, Ontario, Canada
Dr. Abraham Chaiton Medicine Professional Corporation
Toronto, Ontario, Canada
Sunnybrook Regional Cancer Centre
Toronto, Ontario, Canada
Arthur Karasik Medicine Professional Corporation
Toronto, Ontario, Canada
Dr. Sabeen Anwar Medicine Professional Corporation
Windsor, Ontario, Canada
Clinique de Rhumatologie de Montreal
Montreal, Quebec, Canada
Private Practice Dr Louis Bessette
Québec, Quebec, Canada
Centre de sante et services sociaux (CSSS) de Rimouski-Neigette - Hopital regional - Rimouski
Rimouski, Quebec, Canada
CIUSSS de L Estrie CHUS
Sherbrooke, Quebec, Canada
Clinique Jacques Cartier- Rheumatology Division - Université de Sherbrooke
Sherbrooke, Quebec, Canada
Centre de Recherche Musculo Squelettique
Trois-Rivières, Quebec, Canada
Community Rheumatology Care
Saskatoon, Saskatchewan, Canada
Rheumatology Associates of Saskatoon
Saskatoon, Saskatchewan, Canada
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Bessette L, Boulos P, Arendse R, Rahman P, Aseer S, Ruban T, Rachich M, Nantel F, Calce A, Asin-Milan O, Haaland D. Impact of Adherence to Golimumab on Disease Flares in Rheumatoid Arthritis: Results from a Canadian Observational Study. Patient Prefer Adherence. 2025 Jun 25;19:1843-1853. doi: 10.2147/PPA.S516794. eCollection 2025.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CNTO148ARA4010
Identifier Type: OTHER
Identifier Source: secondary_id
CR108555
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.